Accelerate Clinical Trials With AI and Real-Time Data Collaboration
Discover a unified clinical data review and collaboration solution that optimizes the integration and review of complex, ever-changing clinical data.
Companies who are currently submitting reports using the E2B(2) format should already be planning the move to E2B(R3). If a robust safety and pharmacovigilance system is already in place, there are likely just a handful of technical changes that need to be made in order to meet the new regulations. For example, system configuration changes that affect reporting destinations could be required. That said, most companies will likely want to look at additional information that could be sent using E2B(R3) to provide a more robust ICSR.
To learn about E2B(R3), the impact it is likely to have on drug safety business processes, and some ideas for how to move forward, fill out the form below or click here.